WVE-120101 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
8ハンチントン病10

8. ハンチントン病


臨床試験数 : 242 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-003637-42-DE
(EUCTR)
28/07/202009/06/2020A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s DiseaseA Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101
Wave Life Sciences UK LimitedNULLNot RecruitingFemale: yes
Male: yes
50Phase 2France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
2EUCTR2019-003637-42-FR
(EUCTR)
23/07/202005/05/2020A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s DiseaseA Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101
Wave Life Sciences UK LimitedNULLNot RecruitingFemale: yes
Male: yes
50Phase 2France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
3EUCTR2019-003637-42-DK
(EUCTR)
06/07/202002/03/2020A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s DiseaseA Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.1;Level: LLT;Classification code 10012278;Term: Dementia due to Huntington's disease;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101
Wave Life Sciences UK LimitedNULLNot RecruitingFemale: yes
Male: yes
50Phase 2France;Canada;Poland;Australia;Denmark;Germany;United Kingdom
4NCT04617847
(ClinicalTrials.gov)
April 13, 202030/10/2020Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's DiseaseA Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients With Huntington's DiseaseHuntington DiseaseDrug: WVE-120101Wave Life Sciences Ltd.NULLTerminatedN/AN/AAll27Phase 1/Phase 2Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
5EUCTR2019-003637-42-PL
(EUCTR)
11/04/202019/02/2020A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s DiseaseA Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101
Wave Life Sciences UK LimitedNULLNot RecruitingFemale: yes
Male: yes
50Phase 2France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
6EUCTR2016-005095-10-DE
(EUCTR)
20/09/201904/06/2019A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101
Wave Life Sciences UK LimitedNULLNot RecruitingFemale: yes
Male: yes
60Phase 1;Phase 2France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
7EUCTR2016-005095-10-FR
(EUCTR)
11/07/201905/03/2019A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101
Wave Life Science Ltd.NULLNot RecruitingFemale: yes
Male: yes
48Phase 1;Phase 2United States;France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
8EUCTR2016-005095-10-DK
(EUCTR)
26/02/201920/12/2018A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101
Wave Life Sciences UK LimitedNULLNot RecruitingFemale: yes
Male: yes
60Phase 1;Phase 2France;Canada;Poland;Australia;Denmark;Germany;United Kingdom
9EUCTR2016-005095-10-GB
(EUCTR)
02/08/201817/10/2017A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 1;Phase 2Canada;United States;Denmark;Poland;United Kingdom;Australia;France;Germany
10NCT03225833
(ClinicalTrials.gov)
July 17, 201717/7/2017Safety and Tolerability of WVE-120101 in Patients With Huntington's DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's DiseaseHuntington's DiseaseDrug: WVE-120101;Drug: PlaceboWave Life Sciences Ltd.NULLTerminated25 Years65 YearsAll61Phase 1/Phase 2Australia;Canada;Denmark;France;Germany;Poland;United Kingdom